The plasma pharmacokinetics of high dose (1 g) imipenem coadministered with 1 g cilastatin in six normal volunteers.
Eur J Clin Microbiol.
1984 Oct;3(5):468-70. doi: 10.1007/BF02017377. PubMed PMID:
6594235.
Multiple-dose pharmacokinetics of imipenem-cilastatin.
Antimicrob Agents Chemother.
1984 Nov;26(5):715-21. doi: 10.1128/AAC.26.5.715. PubMed PMID:
6595963; PubMed Central PMCID:
PMC180001.
Effect of saturable clearance during high-dose mezlocillin therapy.
Antimicrob Agents Chemother.
1984 Nov;26(5):686-8. doi: 10.1128/AAC.26.5.686. PubMed PMID:
6517555; PubMed Central PMCID:
PMC179995.
Pharmacokinetics of ceftazidime, alone or in combination with piperacillin or tobramycin, in the sera of cancer patients.
Antimicrob Agents Chemother.
1985 Apr;27(4):605-7. doi: 10.1128/AAC.27.4.605. PubMed PMID:
3890730; PubMed Central PMCID:
PMC180104.
Safety and tolerability of multiple doses of imipenem/cilastatin.
Clin Pharmacol Ther.
1985 May;37(5):539-43. doi: 10.1038/clpt.1985.85. PubMed PMID:
3886256.
Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers.
Antimicrob Agents Chemother.
1985 Aug;28(2):235-9. doi: 10.1128/AAC.28.2.235. PubMed PMID:
2939794; PubMed Central PMCID:
PMC180225.
Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum.
Cancer Res.
1985 Dec;45(12 Pt 1):6502-6. PubMed PMID:
3904984.
Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.
Cancer Res.
1986 Mar;46(3):1513-20. PubMed PMID:
2935249.
Imipenem coadministered with cilastatin compared with moxalactam: integration of serum pharmacokinetics and microbiologic activity following single-dose administration to normal volunteers.
Antimicrob Agents Chemother.
1986 Mar;29(3):412-7. doi: 10.1128/AAC.29.3.412. PubMed PMID:
3459390; PubMed Central PMCID:
PMC180405.
Steady-state serum pharmacokinetics of novobiocin and rifampin alone and in combination.
Antimicrob Agents Chemother.
1986 Jul;30(1):42-5. doi: 10.1128/AAC.30.1.42. PubMed PMID:
3752982; PubMed Central PMCID:
PMC176432.
Absolute oral bioavailability of ciprofloxacin.
Antimicrob Agents Chemother.
1986 Sep;30(3):444-6. doi: 10.1128/AAC.30.3.444. PubMed PMID:
3777908; PubMed Central PMCID:
PMC180577.
Dose ranging study and constant infusion evaluation of ciprofloxacin.
Antimicrob Agents Chemother.
1986 Sep;30(3):440-3. doi: 10.1128/AAC.30.3.440. PubMed PMID:
3777907; PubMed Central PMCID:
PMC180576.
Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
Cancer Res.
1987 Jan 15;47(2):617-23. PubMed PMID:
3791246.
Effect of dose size on bioavailability of ciprofloxacin.
Antimicrob Agents Chemother.
1987 Jun;31(6):956-8. doi: 10.1128/AAC.31.6.956. PubMed PMID:
3619432; PubMed Central PMCID:
PMC284222.
Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function.
Antimicrob Agents Chemother.
1987 Jun;31(6):860-4. doi: 10.1128/AAC.31.6.860. PubMed PMID:
3619418; PubMed Central PMCID:
PMC284200.
Bactericidal activity of ciprofloxacin compared with that of cefotaxime in normal volunteers.
Antimicrob Agents Chemother.
1987 Aug;31(8):1177-82. doi: 10.1128/AAC.31.8.1177. PubMed PMID:
3631942; PubMed Central PMCID:
PMC174899.
Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients.
Antimicrob Agents Chemother.
1987 Sep;31(9):1420-2. doi: 10.1128/AAC.31.9.1420. PubMed PMID:
3479047; PubMed Central PMCID:
PMC174953.
Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction.
Cancer Res.
1987 Nov 15;47(22):6104-10. PubMed PMID:
2959359.
An evaluation of optimal sampling strategy and adaptive study design.
Clin Pharmacol Ther.
1988 Aug;44(2):232-8. doi: 10.1038/clpt.1988.142. PubMed PMID:
3293877.
Relationships between renal function and disposition of oral ciprofloxacin.
Antimicrob Agents Chemother.
1988 Oct;32(10):1537-40. doi: 10.1128/AAC.32.10.1537. PubMed PMID:
3190182; PubMed Central PMCID:
PMC175914.
Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate.
Antimicrob Agents Chemother.
1989 May;33(5):618-20. doi: 10.1128/AAC.33.5.618. PubMed PMID:
2751277; PubMed Central PMCID:
PMC172501.
A limited sampling strategy for cyclophosphamide pharmacokinetics.
Cancer Res.
1989 Jun 1;49(11):3129-33. PubMed PMID:
2720671.
A prospective evaluation of optimal sampling theory in the determination of the steady-state pharmacokinetics of piperacillin in febrile neutropenic cancer patients.
Clin Pharmacol Ther.
1989 Jun;45(6):635-41. doi: 10.1038/clpt.1989.84. PubMed PMID:
2659235.
Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580).
Cancer Res.
1989 Jun 15;49(12):3436-40. PubMed PMID:
2720696.
Prospective use of optimal sampling theory: steady-state ciprofloxacin pharmacokinetics in critically ill trauma patients.
Clin Pharmacol Ther.
1989 Oct;46(4):451-7. doi: 10.1038/clpt.1989.164. PubMed PMID:
2791447.
Ciprofloxacin pharmacokinetics in critically ill trauma patients.
Am J Med.
1989 Nov 30;87(5A):70S-75S. doi: 10.1016/0002-9343(89)90027-2. PubMed PMID:
2589390.
Effect of renal function on the bioavailability of ciprofloxacin.
Antimicrob Agents Chemother.
1990 Jun;34(6):1031-4. doi: 10.1128/AAC.34.6.1031. PubMed PMID:
2393263; PubMed Central PMCID:
PMC171752.
Use of plasma cytotoxic activity to model cytotoxic pharmacodynamics of anticancer drugs.
Cancer Chemother Pharmacol.
1991;29(2):133-40. doi: 10.1007/BF00687323. PubMed PMID:
1760856.
Phase I clinical and pharmacokinetic study of zeniplatin, a new platinum complex.
Ann Oncol.
1991 Sep;2(8):589-96. doi: 10.1093/oxfordjournals.annonc.a058026. PubMed PMID:
1793726.
Multiple-dose activate charcoal as adjunct therapy after chronic phenytoin intoxication.
Clin Pharm.
1991 Sep;10(9):711-4. PubMed PMID:
1914431.
Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole.
J Clin Oncol.
1991 Nov;9(11):2027-35. doi: 10.1200/JCO.1991.9.11.2027. PubMed PMID:
1941062.
Approaches to optimal dosing of hexamethylene bisacetamide.
Cancer Chemother Pharmacol.
1992;31(1):37-45. doi: 10.1007/BF00695992. PubMed PMID:
1333894.
Use of adaptive control with feedback to individualize suramin dosing.
Cancer Res.
1992 Jan 1;52(1):64-70. PubMed PMID:
1727387.
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.
Antimicrob Agents Chemother.
1993 May;37(5):1073-81. doi: 10.1128/AAC.37.5.1073. PubMed PMID:
8517694; PubMed Central PMCID:
PMC187901.
Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin.
Antimicrob Agents Chemother.
1993 May;37(5):1065-72. doi: 10.1128/AAC.37.5.1065. PubMed PMID:
8517693; PubMed Central PMCID:
PMC187899.
Predictors of trough concentrations of oral ciprofloxacin.
Pharmacotherapy.
1993 Sep-Oct;13(5):504-7. PubMed PMID:
8247920.
Pharmacokinetics and bioavailability of fluconazole in patients with AIDS.
Antimicrob Agents Chemother.
1993 Oct;37(10):2187-92. doi: 10.1128/AAC.37.10.2187. PubMed PMID:
8257143; PubMed Central PMCID:
PMC192248.
Mathematical examination of dual individualization principles (II): The rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime.
Ann Pharmacother.
1994 Jul-Aug;28(7-8):863-8. doi: 10.1177/106002809402800707. PubMed PMID:
7949501.
Concentration- or effect-controlled clinical trials with sparse data.
Clin Pharmacol Ther.
1994 Jul;56(1):1-8. doi: 10.1038/clpt.1994.93. PubMed PMID:
8033486.
Ticarcillin-clavulanic acid pharmacokinetics in preterm neonates with presumed sepsis.
Antimicrob Agents Chemother.
1994 Sep;38(9):2024-8. doi: 10.1128/AAC.38.9.2024. PubMed PMID:
7811013; PubMed Central PMCID:
PMC284678.
Optimal sampling theory: effect of error in a nominal parameter value on bias and precision of parameter estimation.
J Clin Pharmacol.
1994 Oct;34(10):967-74. doi: 10.1002/j.1552-4604.1994.tb01967.x. PubMed PMID:
7836547.
Effect of aging on atenolol pharmacokinetics and pharmacodynamics.
J Clin Pharmacol.
1995 Aug;35(8):807-14. doi: 10.1002/j.1552-4604.1995.tb04124.x. PubMed PMID:
8522638.
Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants.
Antimicrob Agents Chemother.
1995 Sep;39(9):2042-7. doi: 10.1128/AAC.39.9.2042. PubMed PMID:
8540713; PubMed Central PMCID:
PMC162878.
Pharmacodynamic analysis of sparse data from concentration- and effect-controlled clinical trials guided by a pilot study. An investigation by simulations.
J Pharm Sci.
1996 Jun;85(6):600-7. doi: 10.1021/js9504705. PubMed PMID:
8773956.
Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime.
Antimicrob Agents Chemother.
1996 Aug;40(8):1860-5. doi: 10.1128/AAC.40.8.1860. PubMed PMID:
8843294; PubMed Central PMCID:
PMC163430.
AUIC--the universal parameter within the constraint of a reasonable dosing interval.
Ann Pharmacother.
1996 Sep;30(9):1029-31. doi: 10.1177/106002809603000920. PubMed PMID:
8876868.
Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma.
Clin Pharmacol Ther.
1997 Mar;61(3):301-11. doi: 10.1016/S0009-9236(97)90162-4. PubMed PMID:
9084455.
Pharmacometric analysis of the effect of furosemide on suramin pharmacokinetics.
Pharmacotherapy.
1997 May-Jun;17(3):431-7. PubMed PMID:
9165547.
Pharmacodynamic modeling of the in vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers.
Antimicrob Agents Chemother.
1997 May;41(5):1108-14. doi: 10.1128/AAC.41.5.1108. PubMed PMID:
9145877; PubMed Central PMCID:
PMC163858.
Modeling the response of pneumonia to antimicrobial therapy.
Antimicrob Agents Chemother.
1997 Jun;41(6):1269-74. doi: 10.1128/AAC.41.6.1269. PubMed PMID:
9174182; PubMed Central PMCID:
PMC163898.
What would you like to do?